Brief: Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug In Atopic Dermatitis
02/06/2025 13:22
June 2 (Reuters) - Aclaris Therapeutics Inc ACRS.O: ACLARIS THERAPEUTICS INITIATES PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026 Source text: ID:nGNX87W0hg Further company coverage: ACRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations